Third Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INC

Explicit Guidance:

• Q4 2026: Revenue expected to grow in the "high single-digit range" year-over-year, incorporating a "modest slowdown" in IMS sales to prioritize quality remediation.
• Q4 2026 and subsequent quarters: IMS remediation-related manufacturing expenses expected to remain elevated, with the third-quarter impact of $2–3 million likely to be "a little bit higher" in each of the next two to three quarters.
• Q3 2026 (Context for Guidance): Record quarterly revenue of $207.6 million; IMS sales declined due to remediation; pricing headwinds from 340B duplicate discounts reduced by approx. $2.2 million compared to prior quarters, though not fully resolved.

Business-Segment Outlook:

• Vaccini: Projected strong growth driven by marketing and commercialization efforts; duplicate discounting headwinds persist, but management expects "easier comps" in 2027 as peak double-discounting effects recede. Pricing is not expected to fully recover to historical levels due to structural discounting dynamics.
• Primatine Mist: Sales expected to continue growing; a price increase implemented in Q2 2026 is driving both volume and revenue.
• Ipratropium Bromide: Sales expected to continue increasing from Q3 levels as market share grows; currently the only generic in the market, with annualized sales around $25 million and a long-term opportunity estimated at $50 million.
• Lidocaine: Demand expected to persist into 2027 due to external supplier shortages; however, capacity constraints and a $12.5 million backlog at the IMS facility may limit the volume the company can ship.
• Epinephrine (EpiPen): Sales previously impacted by IMS remediation; future recovery tied to returning IMS to full capacity.
• Insulin Biosimilar (BI-2032): On track for a 2027 commercial launch; identified as a "large market" opportunity with room for entry despite 3–4 existing competitive generics. No firm launch date confirmed yet.
• GLP-1 Generic: Expected to be a "limited opportunity" due to high competitive intensity.
• AMP101 (Intranasal Epinephrine): Phase I development ongoing; refining study design and formulation based on regulatory feedback.
• AMP109 (Peptide-Coupled Docetaxel): Non-clinical studies and manufacturing preparations ongoing; received constructive FDA feedback earlier in the year.
• AMP110 (Synthetic Corticotropin): Evaluating therapeutic indications and conducting non-clinical studies.
• AMP107 (Ophthalmic): Early-stage development for wet AMD and diabetic macular edema; goal to create a differentiated eyedrop alternative to intraocular injections.
• AMP004 (Next-gen Primatine): Formulation with lower global warming potential; filed patent applications with one approved; target to file by end of 2028 to extend IP protection.
• Backlog: IMS facility backlog stands at $12.5 million; goal to reduce this backlog by converting unshipped orders into sales.

Market and Competitive Outlook:

• 340B/Pricing Dynamics: Management anticipates duplicate 340B discounting headwinds to continue impacting net pricing in 2027, though the year-over-year growth comp will improve.
• Supply Chain: IMS facility remains constrained due to added quality controls and resources; full capacity recovery expected "mid-2027" based on Q&A context, though management states they are "pretty close" in the transcript.
• Competition: Glucagon sales face continued pressure from increased competition; Primatine Mist benefits from a differentiated commercial portfolio.
• Market Share: Ipratropium Bromide is gaining share as the sole generic provider in its segment.

Macro / Industry Outlook:

• Regulatory Environment: FDA remains actively involved in IMS remediation with routine updates; no risk of facility shutdown cited, but compliance is critical for resuming full operations.
• Environmental Regulations: EPA/FDA pressure to phase out HFA propellants is driving the development of AMP004 (next-gen Primatine).
• Foreign Exchange: FX fluctuations impacted non-operating expenses in Q3; no specific 2027 FX guidance provided.

Strategic Initiatives:

• IMS Remediation: Ongoing corrective actions to strengthen quality manufacturing systems; prioritizing quality over short-term sales volume to ensure sustainable operations.
• Share Buybacks: Board authorized an additional $50 million share buyback program.
• Manufacturing Expansion: Building out new capacity at IMS and API facilities to utilize underutilized assets and support future launches (e.g., AMP101, Insulin).
• Pipeline Advancement: Disciplined investment in complex generics, biosimilars, and proprietary programs (AMP101, AMP109, AMP110, AMP107).

Risks and Headwinds to Outlook:

• IMS Operations: Potential for continued production delays and elevated manufacturing expenses if remediation takes longer than expected; risk of supply interruption for certain products.
• Pricing Pressure: Continued impact from 340B duplicate discounts and higher rebates may cap net pricing recovery for Vaccini.
• Competitive Headwinds: Intensifying competition in Glucagon and GLP-1 markets; potential generic entry for Ipratropium Bromide in the future (timing unknown).
• Capacity Constraints: Competing demands for resources at IMS may limit the ability to fulfill large backlogs (e.g., Lidocaine) and support other product lines.
• Development Delays: Standard development timelines apply to proprietary programs (e.g., AMP101, AMP109), with no guaranteed approval or launch dates.

Management Tone on the Future:

• Confidence: Management expresses confidence in the "strength of our commercial operations" and the "diversified" portfolio, noting record commercial performance despite headwinds.
• Hedges: Guidance for 2027 is qualitative rather than quantitative; management explicitly states they are "not prepared to give guidance" for 2027 revenue or EPS but expects "strong growth."
• Caveats: Emphasizes that IMS remediation impacts are "operational in nature rather than demand related" and that pricing headwinds will persist but with improving comparability.
• Strategic Focus: Reiterates commitment to "disciplined investment" and "sustainable improvements" in quality systems before scaling volumes.

Miscellaneous:

• Capital Allocation: Focus on investing in commercial portfolio growth, pipeline advancement, and manufacturing capabilities while maintaining a vertically integrated model.
• Financial Metrics: Q3 2026 Net Income $37.8M; Adjusted Net Income $49.3M; Cash Flow from Operations ~$43.3M.